AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Phase 3
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 908
- Registration Number
- NCT03847428
- Locations
- π»π³
Research Site, Hochiminh, Vietnam
A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers
Phase 1
Completed
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT03843060
- Locations
- πΊπΈ
Research Site, Baltimore, Maryland, United States
Durvalumab and Tremelimumab for Pediatric Malignancies
Phase 1
Active, not recruiting
- Conditions
- Pediatric CancerHematological MalignanciesSolid Tumor Pediatric
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT03837899
- Locations
- π¬π§
Research Site, Sutton, United Kingdom
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03836599
- Locations
- πΊπΈ
Research Site, Glendale, California, United States
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Combination Product: BGFCombination Product: GFF
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT03836677
- Locations
- π³π±
Research Site, Zutphen, Netherlands
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Phase 3
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 724
- Registration Number
- NCT03833154
- Locations
- π¬π§
Research Site, Manchester, United Kingdom
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Completed
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 170
- Registration Number
- NCT03833141
- Locations
- π¨π¦
Research Site, Saskatoon, Saskatchewan, Canada
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Phase 3
Completed
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Biological: DurvalumabRadiation: external beam radiation therapy (EBRT) + brachytherapy
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 770
- Registration Number
- NCT03830866
- Locations
- π¨π³
Research Site, Taoyuan City, Taiwan
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- πΉπ
Research Site, Hat Yai, Thailand
A Disease Registry of Patients With Mantle Cell Lymphoma
Completed
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 229
- Registration Number
- NCT03816683
- Locations
- πΊπΈ
Research Site, Milwaukee, Wisconsin, United States
Β© Copyright 2025. All Rights Reserved by MedPath